A Novel Oral Drug For The Treatment Of Moderate To Severe Crohn's Disease Would Earn 40 Percent Patient Share In The U.S. And Europe
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that for the treatment of Crohn's disease, a novel oral drug for the treatment of moderate to severe Crohn's disease would earn 40 percent patient share according surveyed U.S. and European gastroenterologists. Branded oral agents such as budesonide (AstraZeneca/Prometheus's Entocort EC, Dr. Falk's Budenofalk) and oral mesalamine products currently enjoy high patient shares in the Crohn's disease drug market... (Source: Health News from Medical News Today)

Falling HR, Not Beta Blockade, Key to Ivabradine Success in HFFalling HR, Not Beta Blockade, Key to Ivabradine Success in HF
In the SHIFT trial of the heart-rate#8211;lowering agent ivabradine, it was heart-rate reduction per se, not the level of accompanying beta-blocker therapy, that apparently accounted for the newer drug's observed benefits. Heartwire (Source: Medscape Today Headlines)